Gracell Biotechnologies Inc. (GRCL) - Total Assets
Based on the latest financial reports, Gracell Biotechnologies Inc. (GRCL) holds total assets worth $1.89 Billion USD as of September 2023. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Gracell Biotechnologies Inc. (GRCL) net assets for net asset value and shareholders' equity analysis.
Gracell Biotechnologies Inc. - Total Assets Trend (2018–2022)
This chart illustrates how Gracell Biotechnologies Inc.'s total assets have evolved over time, based on quarterly financial data.
Gracell Biotechnologies Inc. - Asset Composition Analysis
Current Asset Composition (December 2022)
Gracell Biotechnologies Inc.'s total assets of $1.89 Billion consist of 90.3% current assets and 9.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 87.8% |
| Accounts Receivable | $26.33 Million | 1.6% |
| Inventory | $-26.33 Million | -1.6% |
| Property, Plant & Equipment | $144.67 Million | 8.7% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2022)
This chart illustrates how Gracell Biotechnologies Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gracell Biotechnologies Inc. stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gracell Biotechnologies Inc.'s current assets represent 90.3% of total assets in 2022, an increase from 86.2% in 2018.
- Cash Position: Cash and equivalents constituted 87.8% of total assets in 2022, up from 8.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is property, plant & equipment at 8.7% of total assets.
Gracell Biotechnologies Inc. Competitors by Total Assets
Key competitors of Gracell Biotechnologies Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
Gracell Biotechnologies Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.73 | 6.77 | 17.20 |
| Quick Ratio | 7.73 | 6.77 | 17.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.54 Billion | $1.42 Billion | $30.13 Million |
Gracell Biotechnologies Inc. - Advanced Valuation Insights
This section examines the relationship between Gracell Biotechnologies Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.39 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -19.6% |
| Total Assets | $1.66 Billion |
| Market Capitalization | $989.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gracell Biotechnologies Inc.'s assets below their book value (0.60x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Gracell Biotechnologies Inc.'s assets decreased by 19.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Gracell Biotechnologies Inc. (2018–2022)
The table below shows the annual total assets of Gracell Biotechnologies Inc. from 2018 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $1.66 Billion | -19.60% |
| 2021-12-31 | $2.06 Billion | +113.50% |
| 2020-12-31 | $964.95 Million | +134.09% |
| 2019-12-31 | $412.22 Million | +177.55% |
| 2018-12-31 | $148.52 Million | -- |
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enable… Read more